Blog

News

The Regulatory Pulse . June 2026

2026-06-17

Share

Five shifts reshaping life sciences this month

Welcome to The Regulatory Pulse, our quarterly read on what is changing across life sciences and what it means for your teams. This quarter, almost every change points the same way: away from document-centric, prescriptive working, and towards risk-based, data-driven ways of operating. Here is the round-up across clinical, pharmacovigilance, regulatory affairs and quality, what is changing, and how we are helping clients respond.

Clinical trials and the TMF

What's changing

The MHRA’s adoption of ICH E6(R3) brings the UK in line with the FDA, EMA and Health Canada at Step 5 of the guideline. Trial oversight moves from a document-centric model to a risk-based, systems-driven one.

Retention has firmed up too. Aligned to EU Regulation 536/2014, 25 years is now the standard for essential document retention, and sponsors and CROs should treat that as the working baseline for all trials, regardless of geography.

At the same time, TMF data increasingly has to move between systems and organisations, through CRO-to-sponsor handovers, Vault-to-Vault transfers and legacy migrations. Weak metadata, inconsistent classifications and unclear country or site links tend to surface only when content has to move.

How we help

We help TMF leads, sponsors and systems teams run a gap analysis against E6(R3) and scope the Veeva Vault configuration changes that follow.

For data that has to move, we provide eTMF migration and transfer-readiness support, from reviewing source packages and confirming target Vault readiness through to mapping rules, dry runs and the reconciliation evidence that confirms the outcome.

What we have built

A free ICH E6(R2) to E6(R3) mapping tool that cross-references every artefact in the TMF Reference Model v3.3.1 against both versions, so gap analysis does not start from scratch.

A voice studio, powered by Kokoro TTS, that produces consistent voiceovers for training videos at scale, which supports the volume of re-training that E6(R3) is generating for site staff, TMF coordinators and vendor onboarding.

An industrialised eTMF migration approach built on reusable templates, mapping workbooks and reconciliation checks, so migrations stay fast without losing traceability.

Pharmacovigilance

What's changing

Regulation (EU) 2025/1466 became fully binding in February 2026 and is the most significant change to European pharmacovigilance in over a decade. It reshapes how Marketing Authorisation Holders design, operate and evidence their PV systems.

Signal management accountability shifts inward. With the standalone signal notification step removed, signal detection and evaluation must be embedded within a company’s own processes, with EudraVigilance treated as one source among many.

Vendor relationships move from informal to contractually binding, with roles, data exchange and audit rights set out explicitly. PSURs must now show how risk minimisation measures are implemented in practice, not just whether they work. AI is moving from experimentation to regulatory expectation, framed by the joint FDA and EMA principles and the ICH M14 guideline on real-world evidence.

How we help

We carry out a structured compliance assessment of your PV system against the updated requirements, identifying where the real exposure lies and in what order to act.

We support third-party governance and contract remediation, and we rebuild the aggregate reporting process so PSURs hold up under inspection, defining how risk minimisation data is collected, owned, reviewed and approved.

What we have built

We apply AI where it makes a measurable difference, across literature screening, ICSR processing and signal detection. Every application runs within a validated quality framework, with human oversight at each critical decision point, so outputs stay traceable and defensible.

Regulatory affairs, from documents to data

What's changing

Regulatory work is shifting from managing documents to managing structured data. The move to eCTD 4.0, defined under ICH M8, requires an overhaul of authoring, publishing and submission. The EMA has accepted voluntary submissions since December 2025, Japan’s mandate landed in April 2026, and mandatory EMA use is expected by 2027.

In parallel, ISO IDMP standards, delivered through the SPOR programme and the Product Management Service, are redefining how product data is generated and shared, and that data cascades across other EMA services. Electronic Product Information based on HL7 FHIR is replacing the Word and PDF formats of the SmPC, package leaflet and labelling, with the EMA roadmap pointing to phased go-lives across 2026.

Together these make data governance a regulatory requirement rather than an operational preference, and they put existing SOPs and working instructions under real pressure.

How we help

Through regulatory intelligence and strategy, we monitor eCTD 4.0, IDMP and ePI developments and translate them into impact assessments on your submissions, dossiers and lifecycle management.

Where the change calls for it, we help redefine data governance frameworks, map gaps against the new requirements, check system compatibility with EMA portals, and review the SOPs and working instructions that need to keep pace.

What we have built

The SmPC Accelerator, built on natural language processing, reads structured regulatory text and maps SmPC content to PMS Chapter 2, RMS reference lists and MedDRA, so large product portfolios take less manual effort.

The Regulatory Hub, developed with Accenture, uses generative AI to interpret EU and national regulations, flag changes and deadlines, and compare current compliance against incoming requirements across markets.

GMP and quality

What's changing

2026 is shaping up as a year of operational accountability in GMP. Regulators expect organisations to justify controls and decisions on the basis of product and patient risk, rather than relying on prescriptive process alone.

Annex 1 remains a focus, with inspections testing whether contamination control strategies work in practice rather than simply being documented. Supply chain oversight continues to attract attention, particularly supplier qualification, raw material traceability and outsourced manufacturing.

AI is beginning to enter regulated GMP activities such as document review, trending and quality analytics, with regulators focused on governance, validation and data integrity. Despite the added complexity, inspection findings keep returning to familiar issues: weak investigations and inconsistent execution.

How we help

We run independent Annex 1 and contamination control assessments, supplier and third-party oversight reviews, GMP quality system maturity assessments and inspection readiness support.

We also help build risk-based GMP strategies for early-phase and advanced therapy manufacturing. The focus is on how systems function in practice and whether they hold up under scrutiny, not documentation alone.

Our experience

Working across a wide range of clients, manufacturing models and regulatory environments gives us a clear view of current inspection themes and the operational approaches proving most effective. That experience lets us offer pragmatic, proportionate support that reflects both today’s expectations and where regulation is heading.

Quality systems and operations

What's changing

Quality is moving away from fragmented, paper-based processes towards cloud-based QMS and SOP platforms, driven by regulator expectations around data integrity, traceability and validation readiness. Companies are consolidating SOP management, training, CAPAs, deviations and change control into unified, validated systems.

As those platforms move to SaaS and cloud, a second pressure appears. The pace of vendor-driven releases, alongside stricter expectations on data integrity and business continuity, is pushing organisations from reactive support towards structured Application Managed Services (AMS), where the goal is operational stability and continuous alignment between business processes and validated systems.

How we help

We implement Agatha Life Sciences for SOPs, controlled documentation, training workflows and electronic signatures within validated systems, and we are expanding our expertise across Veeva Quality Cloud so we can support different QMS ecosystems.

Through our AMS services for GxP environments such as Veeva Vault, SAS and Oracle-based systems, we combine operational support, release governance and impact assessment, so clients can manage evolving platforms with less complexity and more predictability.

What we have built

We are building generative AI into the platforms we support, to give users contextual guidance inside the application, provide assistance across time zones, and standardise support tickets.

A second stream applies retrieval-augmented generation to corporate documentation and procedures, so teams can find the right process answer quickly through AI-assisted search.

The Regulatory Pulse lands once a quarter, one short read across clinical, PV, regulatory and quality. Contact us with your email and we will send the next edition straight to your inbox.

And if any of these shifts is live for your team right now, we are happy to talk it through. No pitch, just a conversation with people who work in this space every day.

Or take the free tool away first:

About Arithmos

With deep expertise in the Life Science Industry, Arithmos supports companies in their digital transformation journey to achieve the best value from technology-enabled solutions and excellence in business operations.

Arithmos team share extensive knowledge of the full GxP regulated environment for both deliveries of services and technologies, and our domains range from Clinical Development, Quality & Compliance, Pharmacovigilance & Safety and, Regulatory Affairs.

Get an assessment

Contact us now to receive further information and an assessment from our experts. We will work with you to evaluate the best approach for your business processes.

From our resources